Apotex and Grünenthal have finalised a licensing agreement granting Apotex exclusive Canadian rights to Nebido, a long-acting injectable testosterone undecanoate therapy for male hypogonadism. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results